KRAS mutation analysis in patients (pts) with locally advanced pancreatic cancer (LAPC) treated with gefitinib and chemoradiation therapy (CT-RT) in a phase I trial.

被引：0
|
作者：
Chen, H.
Raben, D.
Schefter, T.
Kane, M.
McCarter, M.
Olsen, C.
McCoy, K.
Eckhardt, S. G.
Gumerlock, P. H.
机构：
[1] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA
[2] Univ Colorado, Boulder, CO 80309 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4106
引用
收藏
页码：204S / 204S
页数：1
相关论文
共 50 条
  • [31] Phase I dose optimization trial of patupilone in previously treated patients (pts) with advanced colon cancer
    Melichar, Bohuslav
    Casado, Esther
    Tabemero, Josep
    Hosseinzadeh, Sharareh
    Hamm, John
    Wadler, Scott
    Bridgewater, John
    Holland, Jaymes
    Sklenar, Ivo
    Johri, Anandhi
    ANNALS OF ONCOLOGY, 2004, 15 : 85 - 85
  • [32] Updated survival analysis of patients (pts) with uureseetable (UR) or borderline reset-table (BR) locally advanced pancreatic adenocareinonia (LAPC) treated with neoadjuvant FOLFIRINOX
    Khushman, Moh'd M.
    Hosein, Peter Joel
    Velez, Michel
    Carcas, Lauren
    Dammrich, Daniel Joseph
    Hurtado-Cordovl, Jorge
    Parajull, Ritesh
    Pollack, Terri
    Macintyre, Jessica
    Harwood, Ana Paula P.
    Loaiza-Bonilla, Arturo
    Akunyill, Ikechukwu Immanuel
    Restrepo, Maria H.
    Merchan, Jaime R.
    Narayanan, Govindarajan
    Portelance, Lorraine
    Sleeman, Danny
    Levi, Joe U.
    Lima, Calo Max S. Roche
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Phase I Trial of Gemcitabine Dose Escalation with Concurrent Radiotherapy for Patients with Locally Advanced Pancreatic Cancer
    Nishida, Tsutomu
    Tsutsui, Shusaku
    Yamamoto, Katsumi
    Konishi, Koji
    Hayashi, Yoshito
    Iijima, Hideki
    Tsujii, Masahiko
    Takeda, Yutaka
    Kitagawa, Toru
    Yoshioka, Yasuo
    Inoue, Takehiro
    Hayashi, Norio
    PANCREATOLOGY, 2010, 10 (01) : 60 - 65
  • [34] A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer.
    Kortmansky, JS
    O'Reilly, EM
    Minsky, BD
    Puleio, SA
    Winkelmann, J
    Kelsen, DP
    Schwartz, GK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [35] KRAS Mutation Status and Clinical Outcome of Preoperative Chemoradiation With Cetuximab in Locally Advanced Rectal Cancer: A Pooled Analysis of 2 Phase II Trials
    Kim, Sun Young
    Shim, Eun Kyung
    Yeo, Hyun Yang
    Baek, Ji Yeon
    Hong, Yong Sang
    Kim, Dae Yong
    Kim, Tae Won
    Kim, Jee Hyun
    Im, Seock-Ah
    Jung, Kyung Hae
    Chang, Hee Jin
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (01): : 201 - 207
  • [36] Phase I trial of gefitinib with concurrent radiotherapy and fixed dose-rate gemcitabine infusion, in locally advanced pancreatic cancer.
    Maurel, J.
    Martin-Richard, M.
    Conill, C.
    Sanchez, M.
    Petriz, L.
    Ginés, A.
    Gallego, R.
    Cajal, R.
    Navarro, S.
    Fernandez-Cruz, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 204S - 204S
  • [37] Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2
    Gerard, J.
    Azria, D.
    Gourgou-Bourgade, S.
    Martel-Laffay, I.
    Hennequin, C.
    Etienne, P.
    Vendrely, V.
    Conroy, T.
    Francois, E.
    Montoto-Grillot, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [38] Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
    Conroy, Thierry
    Lamfichekh, Najib
    Etienne, Pierre-Luc
    Rio, Emmanuel
    Francois, Eric
    Mesgouez-Nebout, Nathalie
    Vandrely, Veronique
    Artignan, Xavier
    Bouche, Olivier
    Gargot, Dany
    Boige, Valerie
    Bonichon-Lamichhane, Nathalie
    Louvet, Christophe
    Morand, Clotilde
    De La Fouchardiere, Christelle
    Juzyna, Beata
    Rullier, Eric
    Marchal, Frederic
    Castan, Florence
    Borg, Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Phase I Study of Chemoradiation Therapy (nab-Paclitaxel/Gemcitabine) in 18 Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Hibino, Kenji
    Yutaro, Abe
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Akita, Hiroshi
    Takahashi, Hidenori
    Hirata, Takero
    Teshima, Teruki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 147 - 147
  • [40] LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).
    Philip, Philip Agop
    Lacy, Jill
    Dowden, Scot D.
    Sastre, Javier
    Bathini, Venu Gopal
    Cardin, Dana Backlund
    Ma, Wen Wee
    Sobrero, Alberto F.
    Koski, Sheryl L.
    Borg, Christophe
    Tonini, Giuseppe
    Rivera, Fernando
    Hwang, Jimmy J.
    Knoble, Jeanna L.
    Al Baghdadi, Tareq
    Saif, Wasif M.
    Meiri, Eyal
    Kayitalire, Louis
    Li, Jack
    Hammel, Pascal
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345